In 2022, Eli Lilly introduced Mounjaro (tirzepatide), a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, as a direct competitor of Ozempic
Diplopia can be caused by many problems including lens cataracts, corneal infections or scars, hormone problems (eg, Graves disease), diabetes, autoimmune diseases (eg, multiple sclerosis), stroke, brain tumors, brain trauma, and migraine headaches (Kim 2013
78.3% were of European ancestry, 12.9% Latino, and 4.2% African American
February 24, 2024: Ozempic Manufacturer Files Lawsuits Targeting Knockoffs Ozempic Manufacturer Novo Nordisk is not only being sued in federal and state courts for injuries caused by Ozempic (semaglutide), they are filing their own lawsuits too